Crinetics Pharmaceuticals Shares Rise After UBS Initiates Coverage
Crinetics Pharmaceuticals (CRNX) shares rose 8% on Thursday after UBS initiated coverage of the stock with a buy rating and a price target of $55 per share. Trading volume stood at nearly 1.4 million shares compared with a daily average of more than 1.2 million. Price: $41.75, Change: $+3.07, Percent Change: +7.94%
Story updates
07:14:28 PM UTC
SquawkNews
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 2.3%. The iShares Biotechnology ETF (IBB) climbed 2.1%. In corporate news, Crinetics Pharmaceuticals (CRNX) shares jumped 8% after UBS started coverage of the stock with a buy rating and a price target of $55 per share.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.